Nusano (West Valley City, UT) will supply isotopes iodine-125 and actinium-225 to Cellectar Biosciences (Florham Park, NJ) under a new agreement, supporting development of radiotherapeutics including CLR 125 for breast cancer and CLR 225 for pancreatic cancer.
West Valley City, UT - June 27, 2025
Nusano, the West Valley City, Utah-based company redefining the production of medical radioisotopes, has signed a multi-year supply agreement with Cellectar Biosciences, a New Jersey-based clinical-stage biopharma developing radiotherapeutics for hard-to-treat cancers. Under the agreement, Nusano will provide a reliable, long-term supply of iodine-125 (I-125) and actinium-225 (Ac-225), critical isotopes for Cellectar’s clinical pipeline and eventual commercial needs.
The partnership marks another significant milestone in Nusano’s emergence as a key player in the radiopharmaceutical supply chain. Its proprietary production platform, recently announced by TechBuzz, is designed to produce rare and previously hard-to-access isotopes at commercial scale—addressing a critical bottleneck in nuclear medicine and radiotherapeutic development.
“We’re proud to support Cellectar as they work to bring novel, targeted cancer therapies to patients,” said Chris Lowe, CEO of Nusano. “Our platform was built to solve longstanding isotope supply challenges that have slowed innovation. With our ability to produce I-125 and Ac-225 reliably and at scale, we’re helping enable a new era of personalized radiopharmaceuticals.”
For Cellectar, the deal secures isotope access needed to advance key clinical programs, including its upcoming Phase 1b trial of CLR 125 for triple-negative breast cancer and development of CLR 225 for pancreatic cancer.
“Securing a reliable supply of iodine-125 and actinium-225 is a critical milestone in advancing our targeted radiotherapy programs,” said James Caruso, CEO of Cellectar. “Nusano’s production capabilities provide us with confidence in our clinical timelines and future commercial plans.”
The agreement further validates Nusano’s strategic approach to domestic isotope production at a time when the global supply chain for actinium and other alpha emitters remains uncertain and fragmented.
Nusano’s expansion and growing list of partnerships come as radiotherapeutics gain momentum in oncology, with increasing investment in targeted alpha therapy (TAT) platforms and growing demand for Ac-225 in particular. The company recently announced supply agreements with dGenThera, Ratio Therapeutics, and Clarity Pharmaceuticals—further cementing its role as a key domestic supplier in the rapidly scaling radiopharma sector.
For more information, visit nusano.com and cellectar.com.
